Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy

  title={Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy},
  author={Marcello Delano Bronstein},
  journal={Nature Clinical Practice Endocrinology \&Metabolism},
  • M. Bronstein
  • Published 1 March 2006
  • Medicine
  • Nature Clinical Practice Endocrinology &Metabolism
DESIGN This study included patients with microprolactinomas, most of whom had been taking DAs for 2–3 years but then abruptly stopped therapy at least 1 year previously. Before discontinuation, all had normalized prolactin levels and no symptoms of gonadal dys function. Other inclusion criteria were microprolactinoma at the start of the study—symptomatic hyperprolactinemia with micro adenoma (<1 cm) and/or a positive DOMPERIDONE TEST. Exclusion criteria were transient symptoms… 

Hyperprolactinemia and prolactinomas.

Therapeutic effects of Schisandra chinensis on the hyperprolactinemia in rat.

Results show that S. chinensis and its single compound, gomisin N, are regulators of PRL production and may be candidates for treatment of hyperprolactinemia and prolactinoma.

Chemometric Expertise Of Clinical Monitoring Data Of Prolactinoma Patients

The intelligent data analysis reveals the formation of three patterns of prolactinoma patients each one of them described by a set of clinical parameters, so better strategies for considering patients with this diagnosis could be developed and clinically applied.

High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?

Biochemical recurrence in prolactinomas is very frequent, however, in only a few of these patients reinitiation of DA is necessary, and the necessity to restart treatment is necessary.

Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis

A meta-analysis shows that hyperprolactinemia recurs after cabergoline withdrawal in a majority of patients and suggests that a beneficial strategy is associated with tapering CAB dose before withdrawal but not with CAB treatment duration longer than 2 years.

Multivariate statistical interpretation of clinical data of prolactinoma patients

This study reveals some specific relationships between the clinical parameters usually checked at prolactinoma patients allowing in such a way to optimize the monitoring procedure by selecting a

Galactorrhea in an adolescent girl.

  • P. Ryan-Krause
  • Medicine
    Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners
  • 2009



Long‐term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas

Assessment of remission rates in a large cohort of treatment‐naive subjects with microprolactinomas found that dopamine agonist therapy with either cabergoline or bromocriptine for a period of 2 to 3 years in the majority of cases, followed by a trial of treatment withdrawal.

Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia

Recurrence rates two to five years after the withdrawal of cabergoline were 24 percent in patients with nontumoral hyperprolactinemia, 31 percent in Patients with micropr...

Drugs five years later. Bromocriptine.

Withdrawal of bromocriptine therapy is associated in most patients with reversal of its beneficial effects--return of hyperprolactinemia, return of excess growth hormone secretion, and exacerbation of Parkinson's disease.

Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.

A periodic assessment of PRL levels during BRC (and other dopamine-agonist drugs) withdrawal is recommended to avoid the unnecessary maintenance of therapy in a subset of patients with prolactinomas.

Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine.

In the present study bromocriptine treatment seemed to result in permanent cure in 6 out of 16 cases of prolactinomas; nevertheless it is difficult to justify an indefinite medical treatment since the natural history of Prolactinoma remains unknown.

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.

The high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia is confirmed, in a large-scale retrospective study, leaving few patients with unacceptable side effects or inadequate clinical response.